Black Diamond Therapeutics, Inc.
BDTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001701541
No open-market purchases or sales by Black Diamond Therapeutics, Inc. insiders were filed in the last 90 days; 96 institutions reported holding it in 13F filings for Q2 2026, worth $64.9M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Black Diamond Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Black Diamond Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Behbahani Ali | Director | 110,236 | Sep 21, 2026 | 5 |
| Raman Prakash | Director | 51,840 | Sep 21, 2026 | 5 |
| Dhingra Kapil | Director | – | Jun 29, 2026 | 1 |
| Menzel Garry E | Director | – | Jun 29, 2026 | 1 |
| Kulkarni Samarth | Director | – | Jun 29, 2026 | 1 |
| Campbell Shannon | Director | 8,865 | Jun 29, 2026 | 1 |
| Hatzis-Schoch Brent | SEE REMARKS | 83,400 | Jan 23, 2026 | 1 |
| Yurasov Sergey | CHIEF MEDICAL OFFICER | 75,000 | Jan 23, 2026 | 1 |
| Velleca Mark A. | PRESIDENT & CEO | 121,522 | Jan 23, 2026 | 1 |
| Buck Elizabeth | CHIEF SCIENTIFIC OFFICER | 170,192 | Jan 23, 2026 | 1 |
| Jones Erika | SEE REMARKS | 85,150 | Jan 23, 2026 | 1 |
| BB Biotech AG | 10% Owner | 2,733,547 | Mar 20, 2025 | 0 |
| Biotech Growth N V | 10% Owner | 2,733,547 | Mar 20, 2025 | 0 |
| Versant Venture Capital VI, L.P. | 10% Owner | 3,726,341 | Aug 30, 2024 | 0 |
| Versant Voyageurs I, L.P. | 10% Owner | 3,726,341 | Aug 30, 2024 | 0 |
| Versant Voyageurs I Parallel, L.P. | 10% Owner | 3,726,341 | Aug 30, 2024 | 0 |
| Versant Vantage I, L.P. | 10% Owner | 3,726,341 | Aug 30, 2024 | 0 |
| Dixon Wendy L | Director | 38,054 | Apr 3, 2024 | 0 |
| Ni Fang | SEE REMARKS | 125,389 | Feb 15, 2024 | 0 |
| RA Capital Healthcare Fund LP | Director | 3,213,828Indirect | Jul 7, 2023 | 0 |
| Ra Capital Management, L.P. | Director | 3,213,828Indirect | Jul 7, 2023 | 0 |
| Kolchinsky Peter | Director | 3,213,828Indirect | Jul 7, 2023 | 0 |
| Shah Rajeev M. | Director | 3,213,828Indirect | Jul 7, 2023 | 0 |
| RA Capital Nexus Fund, L.P. | Director | 3,213,828Indirect | Jul 7, 2023 | 0 |
| Epstein David M. | SEE REMARKS | 671,423 | Jun 28, 2023 | 0 |
| Mayweg Alexander | Director | – | May 17, 2023 | 0 |
| Ingram Robert Alexander | Other: FORMER DIRECTOR | 42,854 | Dec 19, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 20, 2025 (view filing)9:01 PM ET | Mar 19 | 1 day | BB Biotech AG and 1 other10% Owner | SSale | −5.78M | $2.07 | −$12.0M | −67.9%2.73M after | 7 lots |
| Aug 30, 2024 (view filing)4:16 PM ET | Aug 28 | 2 days | Versant Venture Capital VI, L.P. and 3 others10% Owner | SSale | −221.6K | $6.32 | −$1.40M | −5.6%3.73M after | |
| Oct 19, 2023 (view filing)3:08 PM ET | Oct 17 | 2 days | BB Biotech AG and 1 other10% Owner | PPurchase | +400.0K | $2.34 | +$934.1K | +4.9%8.52M after | |
| Jul 7, 2023 (view filing)4:30 PM ET | Jul 5 | 2 days | RA Capital Healthcare Fund LP and 4 othersDirector | PPurchase | +935.9K | $5.00 | +$4.68M | +41.1%3.21M after | |
| Jul 6, 2023 (view filing) | Jul 5 | 1 day | Behbahani AliDirector | PPurchase | +1.00M | $5.00 | +$5.00M | +29.0%4.45M after | |
| Jul 3, 2023 (view filing)3:36 PM ET | Jun 30 | 3 days | BB Biotech AG and 1 other10% Owner | PPurchase | +1.00M | $5.00 | +$5.00M | +14.0%8.12M after | |
| Jun 29, 2023 (view filing)1:37 PM ET | Jun 27 | 2 days | BB Biotech AG and 1 other10% Owner | PPurchase | +1.74M | $5.49 | +$9.56M | +32.4%7.12M after | |
| Jun 28, 2023 (view filing) | Jun 27 | 1 day | Epstein David M.SEE REMARKS | SSale | −25.0K | $6.70 | −$167.5K | −3.6%671.4K after | 10b5-1 |
| Dec 23, 2022 (view filing) | Dec 21-22 | 2 days | Ni FangSEE REMARKS | PPurchase | +56.4K | $1.28 | +$72.3K | +81.7%125.4K after | 2 lots |
| Nov 2, 2022 (view filing)3:10 PM ET | Oct 31 | 2 days | BB Biotech AG and 1 other10% Owner | PPurchase | +99.8K | $2.25 | +$224.9K | +1.9%5.38M after | |
| Oct 31, 2022 (view filing)3:20 PM ET | Oct 27-28 | 4 days | BB Biotech AG and 1 other10% Owner | PPurchase | +364.7K | $2.02 | +$736.2K | +7.4%5.28M after | 2 lots |
| Oct 25, 2022 (view filing)4:24 PM ET | Oct 21 | 4 days | BB Biotech AG and 1 other10% Owner | PPurchase | +87.8K | $1.51 | +$132.8K | +1.8%4.91M after | |
| Oct 21, 2022 (view filing)3:06 PM ET | Oct 19-20 | 2 days | BB Biotech AG and 1 other10% Owner | PPurchase | +131.4K | $1.36 | +$179.1K | +2.8%4.83M after | 2 lots |
| Jun 30, 2022 (view filing) | Jun 29 | 1 day | Ni FangSEE REMARKS | PPurchase | +25.0K | $2.44 | +$61.0K | +56.8%69.0K after | |
| Apr 29, 2022 (view filing)10:50 AM ET | Apr 27-28 | 2 days | BB Biotech AG and 1 other10% Owner | PPurchase | +405.7K | $2.61 | +$1.06M | +9.5%4.69M after | 2 lots |
| Apr 20, 2022 (view filing)12:56 PM ET | Apr 18-19 | 2 days | BB Biotech AG and 1 other10% Owner | PPurchase | +300.0K | $3.27 | +$980.6K | +7.5%4.29M after | 2 lots |
| Apr 14, 2022 (view filing)12:09 PM ET | Apr 12-13 | 2 days | BB Biotech AG and 1 other10% Owner | PPurchase | +252.6K | $3.48 | +$879.8K | +6.8%3.99M after | 2 lots |